Alamar Capital Management LLC Buys New Shares in DexCom, Inc. $DXCM

Alamar Capital Management LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the first quarter, Holdings Channel reports. The firm purchased 13,605 shares of the medical device company’s stock, valued at approximately $854,000.

Several other hedge funds have also recently added to or reduced their stakes in DXCM. Lido Advisors LLC boosted its holdings in shares of DexCom by 43.6% in the 1st quarter. Lido Advisors LLC now owns 33,324 shares of the medical device company’s stock worth $2,093,000 after purchasing an additional 10,125 shares in the last quarter. Cetera Investment Advisers increased its position in shares of DexCom by 6.5% during the 1st quarter. Cetera Investment Advisers now owns 128,775 shares of the medical device company’s stock valued at $8,087,000 after purchasing an additional 7,852 shares during the last quarter. NewEdge Wealth LLC purchased a new position in shares of DexCom during the 1st quarter valued at about $310,000. Arvest Bank Trust Division purchased a new position in shares of DexCom during the 1st quarter valued at about $3,713,000. Finally, PNC Financial Services Group Inc. lifted its position in DexCom by 13.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 42,456 shares of the medical device company’s stock worth $2,666,000 after buying an additional 4,965 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. This trade represents a 7.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 71,750 shares of company stock valued at $5,163,241. 0.28% of the stock is owned by corporate insiders.

DexCom Stock Down 4.4%

Shares of NASDAQ DXCM opened at $71.43 on Thursday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The firm’s fifty day moving average is $72.01 and its 200 day moving average is $68.89. The company has a market cap of $27.56 billion, a price-to-earnings ratio of 30.53, a PEG ratio of 1.23 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.32 EPS. On average, equities research analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research reports. Bank of America cut their target price on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective for the company. Finally, Mizuho increased their target price on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $85.36.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.